Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 395-400

  Kocher, F ^a   Pircher, A ^a   Mohn Staudner, A ^b   Romeder, F ^c   Duller, W ^d   Steinmaurer, M ^e   Eckmayr, J ^e   Schmid, T ^a   Hilbe, W ^a   Fiegl, M ^a   Greil, R ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b OTTO WAGNER HOSPITAL   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cisplatin; Docetaxel; Induction; Neoadjuvant; Non small cell lung cancer (NSCLC); Radiochemotherapy; Surgery

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLON PERFORATION; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMERUS FRACTURE; INFECTION; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; THROMBOSIS; TREATMENT RESPONSE; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME;

EID: 84926409946     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.019     Document Type: Article

References (23)

1. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
2. Ettinger D.S., Akerley W., Bepler G., Blum M.G., Chang A., Cheney R.T., et al. Non-small cell lung cancer. J Natl Compr Cancer Netw 2010, 8:740-801.
3. Rosell R., Gomez-Codina J., Camps C., Javier S.J., Maestre J., Padilla J., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 26:7-14.
4. Gilligan D., Nicolson M., Smith I., Groen H., Dalesio O., Goldstraw P., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007, 369:1929-1937.
5. Bradbury P.A., Shepherd F.A. Chemotherapy and surgery for operable NSCLC. Lancet 2007, 369:1903-1904.
6. Group NM-aC Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014, 383(9928):1561-1571.
7. Paz-Ares L., Corral J. Treatment for early-stage lung cancer: what next?. Lancet 2014, 383(9928):1528-1530.
8. Robinson L.A., Ruckdeschel J.C., Wagner H., Stevens C.W. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:243S-265S.
9. Burdett S., Stewart L.A., Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006, 1:611-621.
10. Scagliotti G.V., Pastorino U., Vansteenkiste J.F., Spaggiari L., Facciolo F., Orlowski T.M., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012, 30:172-178.
11. Pircher A., Wasle I.K., Mian M., Gamerith G., Ulsperger E., Studnicka M., et al. Docetaxel in the treatment of non-small cell lung cancer (NSCLC) - an observational study focusing on symptom improvement. Anticancer Res 2013, 33:3831-3836.
12. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara P.N., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003, 21:2004-2010.
13. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
14. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003, 21:1752-1759.
15. Pisters K.M., Vallieres E., Crowley J.J., Franklin W.A., Bunn P.A., Ginsberg R.J., et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010, 28:1843-1849.
16. Garrido P., Gonzalez-Larriba J.L., Insa A., Provencio M., Torres A., Isla D., et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007, 25:4736-4742.
17. Huber R.M., Flentje M., Schmidt M., Pollinger B., Gosse H., Willner J., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006, 24:4397-4404.
18. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999, 17:4-11.
19. Douillard J.Y., Gervais R., Quoix E., Le C.T., Le Groumellec A., Lemarie E., et al. Randomized phase III trial for stage III unresectable nonsmall cell lung (NSCLC) cancer: Induction Chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)] followed by conventional radiation (RT) without (arm A) or with daily carboplatin (Cb) (arm B). Final results. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 2005, 49(Suppl. 2):S16.
20. Fiegl M., Hilbe W., Auberger J., Schmid T., Auberger T., Tzankov A., et al. Twelve-year retrospective analysis of lung 15S ASCO Annual Meeting Proceedings cancer-The TYROL Study: Daily routine in 1,424 patients (1995-2006). J Clin Oncol 2008, 26:19063.
21. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
22. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
23. Stupp R., Mayer M., Kann R., Weder W., Zouhair A., Betticher D.C., et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 2009, 10:785-793.